Keynote comment: reimbursement for molecularly targeted anticancer agents

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

From dose to exposure? rethinking fluoropyrimidines as immune checkpoint partners in gastrointestinal cancers.

Current opinion in oncology·2026

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

The New England journal of medicine·2026

Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation Patients at Very High Risk of Stroke: A Budget Impact Analysis in Italy.

Journal of clinical medicine·2026

Staging Modalities in Non-Small Cell Lung Cancer: Evidence-Based Guideline and Systematic Review by the Brazilian Group of Thoracic Oncology.

Clinical lung cancer·2026

Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).

World journal of urology·2026

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

The Lancet. Oncology·2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

The Lancet. Oncology·2026

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

The Lancet. Oncology·2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

The Lancet. Oncology·2026

EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery.

The Journal of cell biology·2026

Baseline EPOS 2020 eligibility and real-world outcomes of dupilumab in CRSwNP: a longitudinal cohort study.

Rhinology·2026

Factors Associated With Chest Tube Output Following Robotic Totally Endoscopic Coronary Artery Bypass Grafting.

Innovations (Philadelphia, Pa.)·2026

Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: Current Evidence and Emerging Strategies.

Journal of clinical medicine research·2026

Low Prevalence of Integrase Inhibitor Resistance Following Treatment Failure: A Real-World Analysis from Hunan Province, China.

Infection and drug resistance·2026

Implementation of a Pharmacogenomic Service in a Pediatric Community Hospital.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026

Related Experiment Videos

Keynote comment: reimbursement for molecularly targeted anticancer agents

Related Concept Videos

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).

From dose to exposure? rethinking fluoropyrimidines as immune checkpoint partners in gastrointestinal cancers.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation Patients at Very High Risk of Stroke: A Budget Impact Analysis in Italy.

Staging Modalities in Non-Small Cell Lung Cancer: Evidence-Based Guideline and Systematic Review by the Brazilian Group of Thoracic Oncology.

Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery.

Baseline EPOS 2020 eligibility and real-world outcomes of dupilumab in CRSwNP: a longitudinal cohort study.

Factors Associated With Chest Tube Output Following Robotic Totally Endoscopic Coronary Artery Bypass Grafting.

Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: Current Evidence and Emerging Strategies.

Low Prevalence of Integrase Inhibitor Resistance Following Treatment Failure: A Real-World Analysis from Hunan Province, China.

Implementation of a Pharmacogenomic Service in a Pediatric Community Hospital.

Related Experiment Videos

Keynote comment: reimbursement for molecularly targeted anticancer agents

Related Concept Videos

Related Articles